Neurocrine Biosciences Inc represents values of innovation, dedication, and patient-centered care. As a leading biopharmaceutical company, Neurocrine is committed to discovering and developing innovative treatments for patients with neurological and endocrine disorders. The company's corporate philosophy focuses on advancing science to improve the lives of individuals suffering from these conditions. Neurocrine takes pride in its research-driven approach and collaboration with healthcare professionals to deliver effective therapies. By combining cutting-edge technology, scientific expertise, and a patient-centric mindset, Neurocrine Biosciences Inc aims to provide solutions that enhance the quality of life for patients in need.

Neurocrine Biosciences Inc primarily operates in the United States, with its headquarters located in San Diego, California. As a biopharmaceutical company, Neurocrine Biosciences is primarily focused on discovering, developing, and commercializing innovative therapeutics for neurological and endocrine-related disorders. While the company's presence may extend to other countries and regions through partnerships and collaborations, its core operations and activities predominantly center around its home country, the United States.

Neurocrine Biosciences Inc has achieved several significant milestones. One notable milestone is the FDA approval of their product called Ingrezza®, which is the first and only treatment for adults with a neurological disorder called tardive dyskinesia. The approval of Ingrezza® marked a major breakthrough in addressing this debilitating condition. Additionally, Neurocrine Biosciences Inc successfully developed and obtained FDA approval for other innovative medications, including Orilissa® for the treatment of endometriosis and Intra-Cellular Therapies for bipolar disorder. Moreover, they have made significant progress in their research and development pipeline, working towards new treatments for various neurological and endocrine disorders. Neurocrine Biosciences Inc continues to be a leading pharmaceutical company making significant contributions to the field.

Neurocrine Biosciences Inc is a biopharmaceutical company headquartered in San Diego, California. Founded in 1992, Neurocrine is focused on discovering, developing, and commercializing innovative medicines for neurological and endocrine disorders. With a strong commitment to scientific excellence, the company has built a diverse portfolio of potential therapeutics addressing various highly unmet medical needs. Neurocrine has successfully brought multiple products to market, including treatments for tardive dyskinesia and endometriosis-associated pain. Their ongoing research and development efforts aim to improve the lives of patients suffering from disorders such as Parkinson's disease, uterine fibroids, and congenital adrenal hyperplasia. Neurocrine Biosciences Inc is recognized as a leading player in the biopharmaceutical industry.

The main competitors of Neurocrine Biosciences Inc in the market include companies like AbbVie Inc., Acadia Pharmaceuticals Inc., and Amicus Therapeutics Inc. These companies operate in the biopharmaceutical industry and compete with Neurocrine Biosciences in developing and marketing innovative drug therapies. Neurocrine Biosciences Inc has established itself as a leading player in the industry, but it faces competition from these companies in terms of research, development, and commercialization of novel treatments for various medical conditions.

Neurocrine Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Neurocrine Biosciences Inc. revolves around developing and commercializing innovative treatments for neurological and endocrine-related disorders. The company focuses on discovering and advancing therapeutics that address unmet medical needs and improve patients' quality of life. Neurocrine Biosciences utilizes its expertise in research and development, clinical trials, and regulatory affairs to bring novel treatments to market. By collaborating with healthcare professionals and industry partners, the company aims to transform patient care in areas such as movement disorders, neuropsychiatric disorders, and hormonal diseases. Neurocrine Biosciences Inc.'s commitment to innovation and patient-centric solutions drives its success in the biopharmaceutical industry.

Pomer Neurocrine Biosciences cena/zisk je 35,25.

Koeficient Neurocrine Biosciences P/S je 6,50.

AlleAktien kvalitatívne skóre pre Neurocrine Biosciences je 6/10.

Tržby spoločnosti očakávaná Neurocrine Biosciences sú 2,27 mld. USD.

Zisk očakávaná Neurocrine Biosciences je 417,47 mil. USD.

Neurocrine Biosciences Inc is an emerging biopharmaceutical company specialized in researching, developing, and marketing innovative therapies for the treatment of neurological and endocrine disorders. The company was founded in 1992 and is headquartered in San Diego, California. Neurocrine Biosciences has four main products in its pipeline, all based on innovation and research. One of these products is Ingrezza, the first FDA-approved medication for the treatment of Tardive Dyskinesia (TD) in adults. The company has also developed another medication called Orilissa, used for the treatment of endometriosis in women. Additionally, the company is working on therapies for children and specialized extracts from patients' immune systems for the treatment of severe diseases. The business model of Neurocrine Biosciences is based on developing innovative products and therapies to help patients with neurological and endocrine disorders. The company utilizes its research and development departments to identify and develop new therapies tailored to patients' needs. The company also has a wide range of collaborations and partnerships with universities and other companies worldwide to accelerate and improve its research. The company also serves various markets and target audiences to maximize its impact. Neurocrine Biosciences focuses on collaborating with hospitals, clinics, physicians, patients, and insurers to ensure that its products and therapies are accessible to all who can benefit from them. The company also dedicates significant time and resources to educate healthcare professionals and physicians to ensure that they recognize and utilize the full potential of its products. In addition to its development pipeline, the company has demonstrated a strong commitment to social responsibility. Neurocrine Biosciences is a member of the Corporate Responsibility Network (CRN), which advocates for promoting patient health and well-being and the community. The company has also adopted a sustainable business leadership policy aimed at reducing environmental impact and integrating social responsibility into all business processes. Overall, the business model of Neurocrine Biosciences is focused on innovation, research, and partnerships to provide worldwide access to innovative therapies and medications for the treatment of neurological and endocrine disorders. The company is well-positioned to tackle future challenges in the medical and pharmaceutical industry and is expected to continue to thrive in this field.

Neurocrine Biosciences vypláca dividendu vo výške 0 USD rozdelenú do výplat počas roka.

Dividenda pre Neurocrine Biosciences sa aktuálne nedá vypočítať alebo spoločnosť nevypláca dividendu.

ISIN spoločnosti Neurocrine Biosciences je US64125C1099.

WKN spoločnosti Neurocrine Biosciences je 900964.

Ticker spoločnosti Neurocrine Biosciences je NBIX.

V posledných 12 mesiacoch spoločnosť Neurocrine Biosciences vyplatila dividendu vo výške . To zodpovedá dividendovému výnosu približne . Pre nadchádzajúcich 12 mesiacov bude pravdepodobne spoločnosť Neurocrine Biosciences vyplácať dividendu 0 USD.

Súčasný výnos z dividend spoločnosti Neurocrine Biosciences je .

Neurocrine Biosciences vypláca dividendu každý štvrťrok. Tá je vyplácaná v mesiacoch .

Neurocrine Biosciences platil každý rok počas posledných 0 rokov dividendu.

Na nasledujúcich 12 mesiacov sa očakávajú dividendy vo výške 0 USD. To zodpovedá dividendovému výnosu 0 %.

Neurocrine Biosciences je priradený sektoru 'Zdravie'.

Aby ste obdržali poslednú dividendu vo výške 0 USD od Neurocrine Biosciences z dňa 21. 7. 2024, museli ste mať akciu v depozite pred ex-dňom 21. 7. 2024.

Posledná dividenda bola vyplatená 21. 7. 2024.

V roku 2023 boli od Neurocrine Biosciences 0 USD vyplatené ako dividendy.

Dividendy spoločnosti Neurocrine Biosciences sú vyplácané v USD.